HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

NAGE

Niagen Bioscience, Inc. (NASDAQ)

Healthcare — Biotechnology

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

None 5 analysts
$3.33
+$0.14 (+4.39%)
Target: $12.60 (278.4%)
Sign in to add NAGE to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$265.22M
P/E Ratio (TTM)15.86
Forward P/E10.41
EPS (TTM)$0.21
Dividend Yield-
Profit Margin14.29%
Revenue Growth3.30%
ROE27.07%
Debt/Equity3.13
Recommendation None
Analyst Target$12.60
Analysts5
Indexes NASDAQ

Technical Indicators

RSI (14)44.3
Beta2.06
SMA 20-
SMA 40-
52-Week High$12.74
52-Week Low$3.18
50-Day Avg$3.90
200-Day Avg$5.73
Avg Volume834.6K
Volume546.9K

Performance Analysis

NEUTRAL

NAGE presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($3.18), which could present a value opportunity.
~ RSI at 44.3 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 3.3% year-over-year.
~ Wall Street consensus is "none" from 5 analysts.
+ Average analyst target of $12.60 implies 278.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:21 UTC

Back to Screener Export Report